Illustration for: Johnson & Johnson Shares Decline Despite Strong Second-Quarter Earnings and Raised Outlook
AI-generated illustration. Visual interpretation does not represent real individuals or scenes.

Johnson & Johnson Shares Decline Despite Strong Second-Quarter Earnings and Raised Outlook

2026-07-16

The BareStory

Johnson & Johnson reported second-quarter financial results that exceeded Wall Street expectations, though its shares declined by over 2% on Tuesday afternoon. The healthcare company posted a 6.6% year-over-year revenue increase to $25.31 billion, beating the LSEG consensus estimate of $25.05 billion. Adjusted earnings per share reached $2.90, ahead of the projected $2.85.

The revenue growth was supported by strong performance in the company's pharmaceutical business, which grew by more than 14% when excluding sales of its immunology drug, Stelara. Stelara has faced increased competition from biosimilar alternatives after losing patent exclusivity in 2025. Growth in the pharmaceutical segment was aided by a 17.3% increase in the cancer portfolio and a 13.9% rise in neuroscience drugs. Additionally, Chief Executive Officer Joaquin Duato noted strong initial momentum for Icotyde, a newly approved daily pill for plaque psoriasis.

Offsetting some of the growth, the company's MedTech division experienced a sales slump in its cardiovascular unit. Chief Financial Officer Joe Wolk attributed the miss to lower-than-expected sales of Abiomed's heart pumps, with cardiovascular sales reaching $2.4 billion compared to the $2.55 billion forecast. Despite this decline, the overall MedTech unit posted worldwide operational sales growth of 3.6%.

Following the second-quarter results, Johnson & Johnson raised its full-year guidance. The company now projects reported sales between $100.8 billion and $101.4 billion, which would mark the first time its annual sales have exceeded $100 billion. It also increased its full-year adjusted earnings per share outlook to a range of $11.60 to $11.75.

Left Perspective

  • Expose Corporate Extraction Limits: Sustained corporate profitability must not come at the expense of accessible healthcare and consumer choice. While Johnson & Johnson celebrates a 14% growth in its pharmaceutical business by maximizing revenue on specialized cancer and neuroscience drugs, the eventual decline of their blockbuster drug Stelara due to patent loss and biosimilar competition demonstrates that public pressure and market alternatives are essential to break monopolistic pricing. True progress is measured by how quickly life-saving treatments become affordable generics, not by how long a corporation can defend high-margin exclusivity.
  • Prioritize Patient-Centric Innovation: Financial performance should be judged by how well a company serves broad public health needs rather than speculative Wall Street expectations. The lower-than-expected sales of Abiomed's heart pumps, which caused the cardiovascular unit to miss its $2.55 billion forecast, highlights the risk of relying on expensive, highly specialized medical devices that may not align with broader clinical adoption or patient affordability. When healthcare giants over-invest in high-cost niche technologies, they divert resources away from equitable, widespread healthcare solutions.
  • Skeptical of Growth Milestones: Commemorating a projected historic milestone of exceeding $100 billion in annual sales reveals a systemic misalignment between corporate wealth and public well-being. Raising full-year adjusted earnings guidance to a range of $11.60 to $11.75 per share signal to consumers that executive strategies remain focused on maximizing shareholder yield rather than lowering treatment costs. This relentless pursuit of top-line revenue growth risks further consolidating market power, ultimately driving up healthcare premiums and out-of-pocket expenses for everyday patients.

Right Perspective

  • Reward Capital Reinvestment Engines: Financial strength and robust cash flows are the primary drivers of medical innovation and long-term systemic stability. Exceeding Wall Street's expectations with a 6.6% revenue increase to $25.31 billion demonstrates that Johnson & Johnson possesses the operational efficiency required to fund expensive, high-risk research and development. Strong performances in the cancer (up 17.3%) and neuroscience (up 13.9%) portfolios validate a business model that successfully offsets natural patent expirations, like Stelara's, through the continuous creation of new intellectual property.
  • Value Market-Driven Diversification: Diversified operational structures shield large healthcare enterprises from sector-specific volatility and temporary setbacks. Although the MedTech division experienced a minor setback in its cardiovascular unit due to slower Abiomed heart pump sales, the overall MedTech unit still managed a 3.6% worldwide operational sales growth. This resilience proves that a broad, diversified product portfolio protects the company's balance sheet from isolated product cycle delays, ensuring consistent dividend payments and institutional stability.
  • Signal Long-Term Value Creation: Forward-looking projections and upward guidance adjustments are the truest indicators of a company's underlying health, far outweighing short-term stock market fluctuations. Raising the full-year sales outlook to a historic range of up to $101.4 billion reflects management's high confidence in newly launched products like the plaque psoriasis pill, Icotyde. For long-term investors, this upward trajectory in projected earnings per share to $11.75 indicates that the company is well-positioned to maintain its industry leadership and generate compounding returns.

How it may affect me

As a U.S. reader:

• You may find more affordable treatment options for plaque psoriasis and other conditions as blockbuster drugs like Stelara face competition from cheaper biosimilar alternatives.

• You may have access to new medical treatments, such as the newly approved daily pill for plaque psoriasis called Icotyde, as the company reinvests its rising revenues into its pharmaceutical pipeline.

• You could experience rising healthcare premiums and higher out-of-pocket expenses if the consolidation of market power and high revenue growth in specialized cancer and neuroscience drugs drive up overall treatment costs.

• You may see long-term stability and consistent dividend payouts if you are an investor in the company, supported by raised full-year sales projections of up to $101.4 billion and a diversified product portfolio that offsets localized sales slumps.

Read the story at